Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTEGRATED BIOPHARMA INCINBP · Entity 8227 | Chief Financial Officer | December 09, 2025 | December 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTEGRATED BIOPHARMA INC
Report date December 09, 2025 · Filed December 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2035-12-09 | Direct | 140,000 |
Reported balance
After 2025-12-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-09 · Grant · Acquired 140,000 · Balance 140,000 F1: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on December 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on December 9, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2025 Filed Dec 10, 2025 22:09 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001345281-25-000011 · primary_doc.xml · derivative · entry 1 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-12-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on December 9, 2026. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:41 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | Disposition to issuerStock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001345281-25-000002 · primary_doc.xml · derivative · entry 2 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 135,000 shares Expires 2025-06-02 F2 · derivative.exercise_date: 72,500 of the options became exercisable on June 2, 2015 and the remaining 62,500 became exercisable in three equal annual installments beginning on June 2, 2016. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:41 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantCommon Stock | 135,000 | $0.09 | $12,150.00 |
DisclosureSEC source: 0001345281-25-000002 · primary_doc.xml · nonDerivative · entry 1 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,200 F1 · kind: 135,000 common stock shares acquired upon exercise of stock option grant dated June 2, 2015. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 17:32 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001345281-24-000007 · primary_doc.xml · derivative · entry 1 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-12-04 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on December 4, 2025. Read SEC document |
| November 25, 2024 Filed Nov 25, 2024 21:59 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | Disposition to issuerStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001345281-24-000005 · primary_doc.xml · derivative · entry 2 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 65,000 shares Expires 2025-06-02 Read SEC document |
| November 25, 2024 Filed Nov 25, 2024 21:59 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantCommon Stock | 65,000 | $0.09 | $5,850.00 |
DisclosureSEC source: 0001345281-24-000005 · primary_doc.xml · nonDerivative · entry 1 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,200 F1 · kind: 65,000 common stock shares acquired upon exercise of stock option grant dated June 2, 2015. Read SEC document |
| November 28, 2023 Filed Nov 29, 2023 22:14 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001345281-23-000007 · primary_doc.xml · derivative · entry 1 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-11-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on November 28, 2024. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 14:51 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | $0.09 Strike: $0.09 | $4,500.00 |
DisclosureSEC source: 0001345281-23-000004 · primary_doc.xml · derivative · entry 2 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 576,667 Underlying: Common Stock · 50,000 shares Expires 2025-06-02 F2 · kind: 50,000 stock options disposed of upon exercise of the portion of a stock option grant dated June 2, 2015. 200,000 stock options for the right to purchase common stock at $0.09 remain available to exercise. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 14:51 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantCommon Stock | 50,000 | $0.09 | $4,500.00 |
DisclosureSEC source: 0001345281-23-000004 · primary_doc.xml · nonDerivative · entry 1 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,200 F1 · kind: 50,000 common stock shares acquired upon exercise of stock option grant dated June 2, 2015. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 23:27 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001345281-22-000003 · primary_doc.xml · derivative · entry 1 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-11-09 F1 · derivative.exercise_price: The Exercise Price of the Stock Option will be the closing prices of the Issuer's Common Stock on the fifth trading day after the filing of the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2022, with the Securities and Exchange Commission. F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on November 9, 2023. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:33 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001345281-21-000001 · primary_doc.xml · derivative · entry 1 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-11-03 F1 · derivative.exercise_price: The Exercise Price of the Stock Option will be the closing prices of the Issuer's Common Stock five trading days after the filing of the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2021, with the Securities and Exchange Commission. F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on November 3, 2022. Read SEC document |
| November 04, 2020 Filed Nov 20, 2020 21:24 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001345281-20-000001 · primary_doc.xml · derivative · entry 1 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-11-04 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on November 4, 2021. Read SEC document |
| May 24, 2019 Filed May 29, 2019 19:36 UTC | INTEGRATED BIOPHARMA INC inbp.ob · Entity 8227 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001345281-19-000001 · primary_doc.xml · derivative · entry 1 Masi Dina · CIK 0001345281 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-05-24 F1 · derivative.exercise_date: The option vests 50% (75,000) on grant date (May 24, 2019) and in three equal annual installments for the remaining 50% (75,000) beginning on May 24, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.